Exagen Inc. Reports Fourth Quarter and Full Year 2019 Results

AVISE® Testing Revenue Drives 24% Revenue Growth March 25, 2020 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent …

Dr. Debra Jeske Zack

Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer

SAN DIEGO, March 24, 2020 — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (CMO), and Anja Kammesheidt, Ph.D., as Chief Scientific Officer (CSO). The addition of Drs. Zack and Kammesheidt to the Exagen team will …

Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE® Testing for Patients Suspected of Autoimmune Disease

Monday, Mar 16, 2020 SAN DIEGO, CA, – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the carecontinuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has entered into a strategic partnership with Sonora Quest, the nation’s largest integrated laboratory system. The agreement provides preferred …

Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020

SAN DIEGO, March 11, 2020 — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will release financial results for the fourth quarter and year-end 2019 after the market closes on Wednesday, March 25, 2020. …

Exagen Inc. Partners with Three California Medical Groups to Offer AVISE® Testing as Covered In-Network Benefit for Their Patients

Monday, March 9, 2020 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the careontinuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced three large medical groups across California have contracted with Exagen Inc. to offer AVISE testing as a covered benefit for patients …

Exagen to Present at Cowen and Company 40th Annual Healthcare Conference

SAN DIEGO, CA, February 18, 2020 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, …

Exagen Announces Addition to Russell 3000® and 2000® Indexes

December 16, 2019 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will be added to the Russell 3000® and 2000® Indexes, effective after the US market opens on December 23, …

Experts in Autoimmunity to Serve on Scientific Advisory Board

SAN DIEGO, CA, December 10, 2019 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq:XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has formed a Scientific Advisory Board (SAB) consisting of national experts in the clinical management of rheumatic autoimmune …

Exagen extends agreement with GSK for a third year

SAN DIEGO, CA, Nov. 22, 2019 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to …

Exagen Inc. Announces $26.2 Million Debt Refinancing

November 21, 2019 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital …